Meeting
2022 ASCO Annual Meeting
Fecal microbiota transplantation followed by anti–PD-1 treatment in patients with advanced melanoma.
Authors
Wilson H. Miller Jr.
Segal Cancer Centre at the Jewish General Hospital, McGill University, Montreal, QC, Canada
Wilson H. Miller Jr., Bertrand Routy , Rahima Jamal , D. Scott Ernst , Diane Logan , Khashayar Esfahani , Karl Belanger , Arielle Elkrief , Rejean Lapointe , Pamela Thebault , Mayra Ponce , Seema Nair Parvathy , Meriem Messaoudene , Micheal Silverman , Saman Maleki , John Gordon Lenehan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03772899
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9533)
DOI
10.1200/JCO.2022.40.16_suppl.9533
Abstract #
9533
Poster Bd #
126
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
First Author: Anna Maloney
Poster
2021 ASCO Annual Meeting
BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.
First Author: Olivier Jules van Not
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2020 ASCO Virtual Scientific Program
Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma.
First Author: Victoria Atkinson